OH-PROAMPAC
20.8.2020 17:33:05 CEST | Business Wire | Press release
ProAmpac, the flexible packaging leader, today announced the launch of their online packaging design configurator branded MAKR (pronounced Make Er). MAKR allows users to remotely create custom three-dimensional package designs in both film and paper formats which can then be prototyped at the company’s Design and Sample Lab (DASL).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200820005615/en/
“Through DASL we have been ideating, designing and prototyping samples in collaboration with customers since 2014. MAKR takes our collaboration process to another level by moving ideation and design to a virtual process. Users can interact in the app with different flexible packaging formats, sizes, shapes, and art in ways that bring their ideas to life no matter where they are located. With so many of our customers working remotely during the pandemic, providing virtual, self-serve capabilities are even more relevant,” states Sal Pellingra, vice president global application & innovation.
MAKR allows users to choose almost any flexible packaging format ProAmpac produces. The user can then custom design their own package employing features such as: package dimensions, closures, handles and even the shape of the pouch. Finally, users can add graphics and submit an order for their completed package design online. ProAmpac’s DASL team will then ensure all details are correct, finalize the order, create and ship the custom prototype directly to the requester.
“This is another great example of ProAmpac’s industry-leading innovation. We’ve consistently differentiated ourselves, not only with world-class manufacturing, but also by providing packaging design services rivaling those of design firms. MAKR expands our collaborative resources and makes it easier for customers to get products from design to market in record time,” said Pellingra. “We’ve already had great feedback from our soft launch partner customers and will build out MAKR and other virtual capabilities to continue to make it easier for customers to bring new packaging ideas to a commercial reality,” Pellingra continued.
MAKR is the newest offering in a growing number of valued-added virtual offerings for ProAmpac customers under the brand name Bridge. Earlier this year ProAmpac launched Bridge Remote Trial Management (RTM), an option that allows a ProAmpac Customer Technical Service Expert to review a customer’s product trials remotely and ensure the packaging products are running efficiently.
“At ProAmpac, serving our customers is our top priority and since the onset of COVID-19 we have experienced increasing demand in virtual support requests. This led us to fast track our digital innovation platforms. MAKR and Bridge RTM are just the beginning. We have more tools and offerings coming soon to ensure our customers are getting the virtual support and service they need,” stated Adam Grose, chief commercial officer. “We feel the launch of MAKR will make it easier for our customers to do business with ProAmpac, which is ultimately the objective behind all our digital product offerings.”
To learn more about ProAmpac’s MAKR, or other offerings available through DASL, contact Nicole Cocuzzi (Nicole.Cocuzzi @Proampac.com) or go to ProAmpac.com/DASL .
Video
Demonstration of MAKR
About ProAmpac
ProAmpac is a leading global flexible packaging company with a comprehensive product offering unparalleled in the industry. We provide creative packaging solutions, industry-leading customer service and award-winning innovation to a diverse global marketplace. We are guided in our work by four core values that are the basis for our success: Integrity, Intensity, Innovation, and Involvement. Cincinnati-based ProAmpac is owned by Pritzker Private Capital along with management and co-investors. For more information, visit ProAmpac.com.
About Pritzker Private Capital
Pritzker Private Capital partners with middle-market companies based in North America with leading positions in the manufactured products, services and healthcare sectors. The firm’s differentiated, long-duration capital base allows for efficient decision-making, broad flexibility with transaction structure and investment horizon, and alignment with all stakeholders. Pritzker Private Capital builds businesses for the long term and is an ideal partner for entrepreneur and family owned companies. For more information, visit PPCPartners.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200820005615/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Venture Global Announces Closing of $1.5 Billion Senior Secured Vessel Financing Facility26.6.2026 22:30:00 CEST | Press release
Venture Global, Inc. (NYSE: VG) announced today that its wholly-owned subsidiary, Venture Global Shipping Holdings, LLC (“VGSH”), has entered into a Credit and Guaranty Agreement providing for a senior secured term loan facility (the “Facility”) in an aggregate principal amount of up to $1,500,000,000. The Facility will mature on June 26, 2032. Deutsche Bank and ING acted as coordinating lead arrangers for the Facility. ING also serves as facility agent and security trustee. VGSH intends to use the net proceeds from the Facility for general corporate purposes, including to reimburse Venture Global LNG, Inc. for payments previously made by it or its affiliates in connection with the acquisition of nine LNG carriers, funding certain reserve accounts, and paying transaction fees and expenses. About Venture Global Venture Global is an American producer and exporter of low-cost U.S. liquefied natural gas (“LNG”) with over 100 MTPA of capacity in production, construction, or development. Ven
Andersen Consulting tilføjer House of Code for at styrke teknologi- og dataløsninger26.6.2026 20:01:00 CEST | Pressemeddelelse
Andersen Consulting forstærker sine kompetencer inden for teknologisk transformation gennem en samarbejdsaftale med House of Code, en global virksomhed med hovedkvarter i USA, der specialiserer sig i datadrevne platforme, automatisering og agentbaserede ai-løsninger. House of Code blev stiftet i 2001 og udvikler softwareløsninger samt yder rådgivning til energihandels- og finanssektoren med kunder, der spænder over hedgefonde, kapitalfonde og forsyningsvirksomheder. Virksomheden besidder dyb ekspertise inden for energihandel og risikostyring og hjælper organisationer med systemimplementering, forretningstransformation, dataautomatisering og ai-underbygget modernisering af arbejdsgange. Deres proprietære platform, Enterprise Platform for Integrated Compliance (EPIC), skaber en mere effektiv datastyring, automatiserer rapporteringsprocesser, forbedrer den driftsmæssige gennemsigtighed på tværs af virksomhedssystemer og skaber et fundament for opbygning af intelligente, agentbaserede arbe
Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 20:00:00 CEST | Press release
Receives AI Governance & Risk Excellence Award at OpenAI Partner SummitCapco’s UK AI Lab wins OpenAI Codex Hackathon Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solutio
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
